Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics
26 January 2022 - 12:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and Artisan Development Labs Inc.
(DBA Artisan Bio), an immune cell engineering company developing
next-generation cell therapies, today announced a collaboration to
discover novel antibodies against five undisclosed targets, with an
option to expand with additional targets.
Under the terms of the collaboration, Twist will leverage its
proprietary Library of Libraries to discover novel antibodies
directed against Artisan’s immunotherapy targets. Artisan will
leverage its Immune Cell Engineering Foundry and STAR Guides to
develop custom cell therapeutics. Twist will receive upfront
technology access and project fees for each program, success-based
clinical, regulatory and commercial milestones, as well as
royalties on product sales.
“Twist’s novel and diverse libraries provide access to a wide
range of unbiased antibodies. We look forward to bringing together
the massively parallel DNA synthesis platform of Twist with our own
massively parallel cell engineering platform to develop the next
generation of cell therapeutics,” said Ryan T. Gill, Ph.D., CEO of
Artisan Bio.
“CRISPR presents a myriad of opportunities to revolutionize
human health. Artisan has a unique approach that combines a deep
understanding of this gene-editing technology with advanced AI
analysis,” commented Emily M. Leproust, Ph.D., CEO and co-founder
of Twist Bioscience. “Our collaboration with Artisan will leverage
our innovative antibody discovery capabilities to help translate
this cutting-edge approach into novel cell therapies.”
About Artisan Bio Artisan’s vision is to design, build,
and deliver cells and precision engineering processes that advance
cellular therapies across a broad range of human health
indications. The company’s cell engineering and data analysis
foundry enables the generation of safer and more efficacious cell
therapies. By engaging in strategic collaborations with innovative
partners, Artisan seeks to deliver customizable cell engineering
solutions that meet the complexities associated with
next-generation cell therapies. Artisan has offices in Denver,
Colorado and Toronto, Canada. For more information, please visit
http://artisancells.com/.
About Twist Bioscience Corporation Twist Bioscience is a
leading and rapidly growing synthetic biology and genomics company
that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform
is a proprietary technology that pioneers a new method of
manufacturing synthetic DNA by “writing” DNA on a silicon chip.
Twist is leveraging its unique technology to manufacture a broad
range of synthetic DNA-based products, including synthetic genes,
tools for next-generation sequencing (NGS) preparation, and
antibody libraries for drug discovery and development. Twist is
also pursuing longer-term opportunities in digital data storage in
DNA and biologics drug discovery. Twist makes products for use
across many industries including healthcare, industrial chemicals,
agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements This
press release contains forward-looking statements. All statements
other than statements of historical facts contained herein,
including but not limited to the ability of the collaboration to
discover novel antibodies against current and future targets and
the achievement of any clinical, regulatory or commercial
milestones, are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Annual Report Form 10-K filed with the Securities and Exchange
Commission on November 23, 2021 and subsequent filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220125005557/en/
For Twist Bioscience Angela Bitting SVP, Corporate
Affairs (925) 202-6211 media@twistbioscience.com For Artisan
Bio Ken LaMontagne VP Business Development (201) 650-0636
bd@artisancells.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024